非类固醇内注射用于非传染性乌维性囊性黄斑胀:系统性审查和元分析
Farzan Kianersi1, Abdolreza Rezaeian-Ramsheh1, Alireza Rahimi2
1Isfahan Eye Research Center, Department of Ophthalmology, Isfahan University of Medical Sciences, Isfahan, Iran.
European journal of ophthalmology
|November 7, 2023
概括
非类固醇内注射有效治疗非传染性乌维性囊性黄斑胀 (CME). 这一元分析显示,中央黄斑厚度和视力敏度的显著改善,支持它们用于CME管理.
科学领域:
- 眼科医生 眼科 眼科
- 视网膜疾病 视网膜疾病
- 炎症性眼睛疾病 炎症性眼睛疾病
背景情况:
- 非传染性乌维性囊性黄斑 (CME) 在维护视力方面构成了重大挑战.
- 静脉内注射越来越多地被探索用于管理炎症性眼内疾病.
- 对无性CME的非类固醇药物的系统评估对于治疗指南至关重要.
研究的目的:
- 系统地审查和综合关于非感染性脑膜硬性硬性肌痛的非类固醇静脉注射的证据.
- 评估这些治疗方法在改善视力敏度和减少斑点厚度方面的有效性.
主要方法:
- 在主要数据库 (PubMed,Scopus,Web of Science等) 进行全面的文献搜索. 在2022年5月之前.
- 随机效应模型元分析以估计中央黄斑厚度 (CMT) 和视力敏度 (VA) 的变化.
- 进行元回归分析,以考虑潜在的混因素.
主要成果:
- 17项研究 (258只眼睛) 显示CMT显著降低,VA治疗后改善.
- 对抗血管内皮生长因子 (VEGF),infliximab,甲状腺 (MTX) 和二甲的亚组分析都显示出显著的益处.
- 对于脑膜性CME的各种非类固醇内药物,一致的积极结果.
结论:
- 非类固醇内注射,包括贝瓦西祖马布,拉尼比祖马布,因弗力西马布,甲状腺 (MTX) 和迪克洛菲纳克,是有效的治疗选择.
- 这些药物为患有非传染性脑膜炎CME的患者提供了有前途的治疗策略.
- 进一步的研究可能会完善治疗方案,并确定特定患者个人资料的最佳药物.
相关概念视频
01:27Open Angle Glaucoma: Treatment
459
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
459
01:28Angle Closure Glaucoma: Treatment
534
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
534